Altimmune Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.1%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$0.71next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly332MTarget: Maintain sufficient runway to fund operations into 2027
Research and Development (R&D) Expenses Quarterly16.2MTarget: Disciplined capital allocation for Phase 3 trial startup
Net Loss Quarterly22.6MTarget: Manageable cash burn during pre-commercial clinical stage
Watch Items
- Initiation of PERFORMA Phase 3 MASH TrialTrigger: Second Half of 2026Action: Verify trial site activation, patient screening, and first patient dosed
- Topline Data from RECLAIM Phase 2 AUD TrialTrigger: Third Quarter of 2026Action: Evaluate efficacy endpoints (reduction in alcohol consumption) and safety profile
- Enrollment Completion in RESTORE Phase 2 ALD TrialTrigger: Third Quarter of 2026Action: Confirm full enrollment of approximately 100 patients
- Strategic Partnering Discussions for PemvidutideTrigger: Ongoing throughout 2026Action: Monitor for co-development or licensing agreements to support Phase 3 programs
Research as of 19 Jun 2026